Related Experiment Video
Updated: Jul 2, 2025

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells
Published on: December 29, 2012
NKT Agonist-Antigen Conjugates as Cancer Vaccines
Benjamin J Compton1, Gavin F Painter2
1Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand.
Abstract:
Natural killer T (NKT) cells are a population of innate-like T cells capable of enhancing both innate and adaptive immune responses. Co-delivering an NKT cell agonist and antigen can provide molecular signals to antigen-presenting cells, such as dendritic and B cells, that facilitate strong antigen-specific adaptive immune responses. Accordingly, there has been a significant number of developmental NKT cell-dependent vaccine therapies developed, particularly in the last decade, with many incorporating cancer antigens. In this review, we summarize studies that chemically conjugate the NKT cell agonist and antigen as an effective strategy for agonist-antigen co-delivery to drive antitumor responses.
Insights
Chemically linking NKT cell agonists and antigens enhances immune responses. This strategy effectively drives antitumor immunity by co-delivering key signals to immune cells.
Area of Science:
- Immunology
- Vaccinology
- Cancer Therapy
Background:
- Natural killer T (NKT) cells bridge innate and adaptive immunity.
- NKT cell activation enhances immune responses.
- Antigen-specific adaptive immunity is crucial for vaccine efficacy.
Conclusions:
- Conjugating NKT cell agonists with antigens is a potent strategy for enhancing antitumor immunity.
- This method optimizes molecular signaling to antigen-presenting cells.
- NKT cell-based cancer vaccines represent a significant area of therapeutic development.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
18:08Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
Published on: December 31, 2007
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...